

# ESMO Virtual Advanced Course on EGFR-Mutated NSCLC: A Rapidly Evolving Paradigm With Unanswered Questions

## Programme

**ESMO VIRTUAL  
ADVANCED COURSE**

**21-23 JUNE 2021**

**Co-Chairs**

Pasi A. Jänne, United States  
Tony S. K. Mok, Hong Kong  
Solange Peters, Switzerland

# ESMO VIRTUAL ADVANCED COURSE PROGRAMME

## EGFR-MUTATED NSCLC: A RAPIDLY EVOLVING PARADIGM WITH UNANSWERED QUESTIONS

21-22-23 June 2021

---

**CO-CHAIRS:** Pasi A. Jänne, United States  
Tony S. K. Mok, Hong Kong  
Solange Peters, Switzerland

**SPEAKERS:** Fabrice Barlesi, France  
Reinhard Büttner, Germany  
Natasha Leighl, Canada  
Keunchil Park, South Korea  
Antonio Passaro, Italy  
Luis Paz-Ares, Spain  
Frédérique Penault-Llorca, France  
Masahiro Tsuboi, Japan  
James C.-H. Yang, Taiwan

---

### LEARNING OBJECTIVES

- Understanding the biology of EGFR in normal and malignant cells
- Gaining insights in the spectrum of EGFR activating mutations, platforms, and strategies for molecular testing
- Understanding the role of biomarkers in selecting NSCLC patients for EGFR TKIs
- Discussing state-of-the-art therapeutic strategies and clinical research in EGFR mutated NSCLC
- Managing toxicity and how to use EGFR TKIs in specific subgroups of patients

---

### ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to [esmo.org](http://esmo.org).

---

### ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

**AstraZeneca** 

---

### ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4  
6900 Lugano  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)

**ESMO** GOOD SCIENCE  
BETTER MEDICINE  
BEST PRACTICE

All timings are to be considered GMT+8 (Singapore Local Time)

## Monday, 21 June 2021

---

- 15:00-15:10**     **Welcome and introduction**  
Pasi A. Jänne, US  
Tony S.K. Mok, HK  
Solange Peters, CH
- 15:10-16:00**     **Session 1**
- 20'     The structure, function and role of EGFR in normal cell homeostasis  
Reinhard Büttner, DE
- 20'     EGFR activating mutations from a molecular biology perspective: Incidence and biology  
Frédérique Penault-Llorca, FR
- 10'     Discussion
- 16:00-16:10**     *Break*
- 16:10-17:20**     **Session 2**
- 20'     Treatment of uncommon EGFR mutations (except exon 20)  
Antonio Passaro, IT
- 20'     Single agent EGFR inhibitor for classical exon 19/21 mutations  
Luis Paz-Ares, ES
- 20'     Treatment of exon 20 mutation  
Pasi A. Jänne, US
- 10'     Discussion
- 17:20-18:15**     **Session 3**
- 20'     Resistance to EGFR TKIs: Biological and clinical perspective  
Pasi A. Jänne, US
- 20'     New drugs in development for EGFR TKIs resistance  
Tony S. K. Mok, HK
- 15'     Discussion
- 18:15-18:45**     **Session 4**
- 20'     Third generation EGFR TKIs for the first line management of patients EGFR-mutated NSCLC: the clinical evidence and ongoing clinical research  
Keunchil Park, KR
- 10'     Discussion

18:45-19:00      Questions and answers

## Tuesday, 22 June 2021

---

15:00-15:30      **Session 5**  
20'      Immunotherapy for EGFR mutated NSCLC  
Solange Peters, CH

10'      Discussion

15:30-16:00      **Session 6**  
20'      Management of CNS metastases/leptomeningeal disease  
Natasha Leigh, CA

10'      Discussion

16:00-16:45      **Session 7**  
Debate: Combinations of chemotherapy and EGFR TKIs in EGFR-mutated NSCLC

20'      Added value  
James C.-H. Yang, TW

20'      Overtreatment  
Natasha Leigh, CA

5'      Voting

16:45-16:55      *Break*

16:55-17:25      **Session 8**  
20'      The role of EGFR TKIs in the adjuvant and neo-adjuvant setting  
Masahiro Tsuboi, JP

10'      Discussion

17:25-17:40      Questions and answers

## Wednesday, 23 June 2021

---

15:00-17:25      **Workshop sessions**  
15' Introduction based on clinical cases presented by speakers  
30' Discussion

**Workshop 1**     **Integrating EGFR TKIs in the management of advanced NSCLC patients with oligometastatic disease and progression in sanctuary sites**  
45'     Natasha Leighl, CA  
         Tony S. K. Mok, HK

**Workshop 2**     **Platforms and optimal sequence strategies for NSCLC molecular testing in the molecular oncology era**  
45'     Solange Peters, CH  
         Frédérique Penault-Llorca, FR

16:30-16:40     *Break*

**Workshop 3**     **Liquid biopsy applications for EGFR mutational profiling and monitoring of disease course**  
45'     Fabrice Barlesi, FR  
         Pasi A. Jänne, US

17:25-17:45     **Synthesis and wrap-up**  
         Pasi A. Jänne, US  
         Tony S.K. Mok, HK  
         Solange Peters, CH